Author:
Montalbano Marzia,Neff Guy W.,Yamashiki Noriyo,Meyer Douglas,Bettiol Marina,Slapak-Green Gabriella,Ruiz Phillip,Manten Emory,Safdar Kamran,O’Brien Christopher,Tzakis Andreas G.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference15 articles.
1. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.;Sehgal;Therap Drug Monit,1995
2. Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes.;Bansbach;Inflammation Res,1995
3. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.;Brattstrom;Transplant Proc,1996
4. A retrospective review of sirolimus(Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection.;Neff;Liver Transplant,2003
5. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.;Cotterell;Clinical Transplant,2002
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献